Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.784 EUR | +4.26% | -1.38% | -90.37% |
Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
Business Summary
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Number of employees: 15
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutic Products
100.0
%
| 0 | nan % | -4 | 100.0 % | - |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Germany
100.0
%
| 0 | nan % | -4 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Samir Shah
BRD | Director/Board Member | 63 | 21-12-31 |
Director/Board Member | 56 | 18-08-30 | |
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Claudia Riedl
BRD | Director/Board Member | 54 | 21-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,066,808 | 17,348,972 ( 66.56 %) | 0 | 66.56 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-90.37% | 21.31M | |
+33.37% | 50.85B | |
+1.86% | 42.82B | |
+49.45% | 42.03B | |
-4.22% | 29.55B | |
+11.66% | 26.11B | |
-21.10% | 19.13B | |
+7.44% | 13.05B | |
+27.59% | 12.16B | |
+23.71% | 12.08B |
- Stock Market
- Equities
- VVY Stock
- Company Vivoryon Therapeutics N.V.